Ultragenyx Pharmaceutical Inc. RARE
2 targets with a reported result
Releases of the last 3 yearsThe numbers RARE said it expected, in its earnings releases, next to what it then reported for the same period.
Target by target
Each target, with the sentence it came from · release and 10-Q or 10-K
| Target | What the company said | Reported | Result | |
|---|---|---|---|---|
| Revenue Fiscal 2027 |
Given $100.00M to $110.00M release Feb 12, 2026
|
– | Not reported yet | |
The company's wordsDojolvi revenue in the range of $100 million to $110 million 3 Strategic restructuring plan and path to profitability in 2027 release Feb 12, 2026 | ||||
| Revenue Fiscal 2026 |
Given $500.00M to $520.00M release Feb 12, 2026
Raised $730.00M to $760.00M release May 5, 2026
Kept $730.00M to $760.00M release Aug 4, 2026
Kept $730.00M to $760.00M release Nov 3, 2026
|
– | Not reported yet | |
The company's wordsFinancial Guidance and Strategic Restructuring Plan 2026 revenue guidance … Crysvita revenue in the range of $500 million to $520 million , reflecting growing underlying global demand partially offset by expected timing of ordering patterns in Brazil release Feb 12, 2026 The company reaffirms its full year 2026 total revenue guidance of $730 million to $760 million, which excludes revenue from potential new product launches. release May 5, 2026 The company reaffirms its full year 2026 total revenue guidance of $730 million to $760 million, which excludes revenue from potential new product launches. release Aug 4, 2026 The company reaffirms its full year 2026 total revenue guidance of $730 million to $760 million, which excludes revenue from new product launches. release Nov 3, 2026 | ||||
| Revenue Fiscal 2025 (ended Dec 31, 2025) |
Given $640.00M to $670.00M release Jan 13, 2025
Kept $640.00M to $670.00M release Feb 13, 2025
Kept $640.00M to $670.00M release May 6, 2025
Kept $640.00M to $670.00M release Aug 5, 2025
Kept $640.00M to $670.00M release Nov 4, 2025
|
$673.00M 10-K filed 2026-02-18 |
Above the range | |
The company's words2025 expected total revenue guidance of $640 million to $670 million release Jan 13, 2025 2025 Financial Guidance … Total revenue to be in the range of $640 million to $670 million release Feb 13, 2025 Reaffirm 2025 Financial Guidance: Total revenue between $640 million to $670 million, Crysvita revenue of $460 million to $480 million, and Dojolvi revenue of $90 million to $100 million release May 6, 2025 Reaffirm 2025 Revenue Guidance: Total revenue between $640 million to $670 million, Crysvita revenue of $460 million to $480 million, and Dojolvi revenue of $90 million to $100 million release Aug 5, 2025 Reaffirm 2025 Revenue Guidance: Total revenue between $640 million to $670 million, Crysvita revenue of $460 million to $480 million, and Dojolvi revenue of $90 million to $100 million release Nov 4, 2025 | ||||
| Revenue Fiscal 2024 (ended Dec 31, 2024) |
Given $500.00M to $530.00M release Jan 8, 2024
Kept $500.00M to $530.00M release Feb 15, 2024
Kept $500.00M to $530.00M release May 2, 2024
Raised $530.00M to $550.00M release Nov 5, 2024
|
$560.23M 10-K filed 2025-02-19 |
Above the range | |
The company's words2024 expected Total Revenue guidance between $500 million to $530 million, Crysvita revenue of $375 million to $400 million, and Dojolvi revenue of $75 million to $80 million release Jan 8, 2024 2024 Financial Guidance: Total Revenue between $500 million and $530 million, Crysvita revenue of $375 million to $400 million, and Dojolvi revenue of $75 million to $80 million release Feb 15, 2024 Reaffirmed 2024 expected total revenue guidance between $500 million to $530 million, Crysvita revenue of $375 million to $400 million, and Dojolvi revenue of $75 million to $80 million release May 2, 2024 Reaffirmed 2024 expected total revenue guidance of $530 million to $550 million release Nov 5, 2024 | ||||
Targets are read from the sentences of the EX-99 exhibits of 8-K item 2.02 filings (15 releases since 2024-01-08), without AI; in outlook tables only the first column is read. The result compares the reported number with the last range given before the period was reported. Results come from SEC's XBRL company facts, as first reported. A company's target can use its own definition (META's capital expenditures include finance lease payments, for example), so read the quote.
Sources
The outlook sentences of each earnings release (8-K item 2.02, exhibit 99), read without AI; results from SEC's XBRL company facts, as first reported.
Also
Earnings releases: each release in full.
Work with it
Excel workbook · CSV. Google Sheet that stays up to date: paste =IMPORTDATA("https://tickdelta.com/company/RARE/export.csv") into a cell.